Donne A J, Rothera M P, Homer J J
University Department of Otolaryngology and Head and Neck Surgery, Manchester Royal Infirmary, UK.
Int J Pediatr Otorhinolaryngol. 2008 Jul;72(7):939-44. doi: 10.1016/j.ijporl.2008.04.003. Epub 2008 May 27.
Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing. Cidofovir is potentially harmful. Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy.
Pubmed was searched using the terms cidofovir and papillomatosis. Comparisons were made between published articles.
Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients. Cidofovir did result in a significant improvement of papillomatous lesions in the majority (60%) of patients despite the use of different regimes of cidofovir administration. There was no unifying protocol in use. A partial response was demonstrated in 29% of patients. 7.5% had no response however, an additional 3.5% patients were lost to follow-up. No malignant change was reported.
Cidofovir does appear to be effective in improving the outcome of patients with RRP. There are no reports of malignant transformation despite concerns raised by toxicology studies.
西多福韦是复发性呼吸道乳头状瘤病（RRP）目前最新的辅助治疗药物，其使用正在增加。西多福韦有潜在危害。耳鼻喉科医生应了解西多福韦的科学知识并查阅有关该疗法效果的当前已发表数据。
使用“西多福韦”和“乳头状瘤病”等术语在PubMed上进行检索。对已发表的文章进行比较。
在1998年至2006年期间共鉴定出13篇文章，涉及142例患者的治疗。尽管使用了不同的西多福韦给药方案，但西多福韦确实使大多数（60%）患者的乳头状瘤病变有显著改善。当时没有统一使用的方案。29%的患者有部分反应。7.5%的患者无反应，不过，另有3.5%的患者失访。未报告有恶性变化。
西多福韦似乎确实能有效改善RRP患者的治疗结果。尽管毒理学研究提出了担忧，但尚无恶性转化的报告。
